journal article·2018-11-12Open access

Synergistic co-delivery of doxorubicin and melittin using functionalized magnetic nanoparticles for cancer treatment: loading and in vitro release study by LC–MS/MS

Marjan Hematyar, Majid Soleimani, Ali Es-haghi, Ali Rezaei Mokarram

Abstract

In this study, citric acid-functionalized Fe3O4 magnetic nanoparticles (CA-MNPs) were prepared via a coprecipitation method and were fully characterized. Doxorubicin (DOX) and melittin (MEL), as anticancer agents, were loaded onto CA-MNPs surface through electrostatic interactions with the aim to achieve an effective co-delivery system for cancer therapy. The loading efficiency and in vitro release profiles of DOX and MEL were investigated by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The MS/MS step was performed in the selected reaction monitoring (SRM) mode which enabled simultaneous quantification of the analytes with high specificity and sensitivity. An excellent loading efficiency of about 100% was achieved for DOX and MEL in a drug to nanocarrier ratio of 1:10. The in vitro release of the drugs from CA-MNPs was evaluated for 8 h at pH 7.4, 5.5 and 4.5. The experimental results revealed that the release behaviour of both of the anticancer agents was strongly pH-dependent and significantly enhanced at pH 4.5. The in vitro MTT assay on MCF-7 breast cancer cell line exhibited a synergistic effect between DOX and MEL which led to substantially greater antitumor efficacy, compared to single administration of these anticancer agents at equivalent doses. The results indicated that the co-delivery system of (DOX/MEL)-loaded CA-MNPs is highly capable to be used in magnetically targeted cancer therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Healthcare and Venom Research · Bee Products Chemical Analysis · Leech Biology and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, Imam Khomeini International University (IKIU)

Department of Physico Chemistry, Razi Vaccine & Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO)

Department of QA, Razi Vaccine & Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO)

Funding

Research Council of Imam Khomeini International University · Research Council of Razi Vaccine and Research Institute

References (45)

Show source-provided references
1. 10.1080/0192623070132033710.1080/01926230701320337 ↗
2. 10.1038/nrc152910.1038/nrc1529 ↗
3. 10.1021/nn401079610.1021/nn4010796 ↗
4. 10.1016/j.ijpharm.2013.06.01710.1016/j.ijpharm.2013.06.017 ↗
5. 10.1039/C5RA15313A10.1039/C5RA15313A ↗
6. 10.1016/j.addr.2015.10.02110.1016/j.addr.2015.10.021 ↗
7. 10.1016/j.jconrel.2014.05.00210.1016/j.jconrel.2014.05.002 ↗
8. Omar HEDM. The biological and medical significance of poisonous animals. J Biol Earth Sci. 2013;3:M25–M41.
9. 10.1016/S2221-1691(13)60042-810.1016/S2221-1691(13)60042-8 ↗
10. 10.1016/j.etap.2013.06.00910.1016/j.etap.2013.06.009 ↗
11. 10.3390/toxins704112610.3390/toxins7041126 ↗
12. 10.4014/jmb.1608.0804210.4014/jmb.1608.08042 ↗
13. 10.1016/j.jconrel.2014.03.00510.1016/j.jconrel.2014.03.005 ↗
14. 10.1007/s10555-011-9339-310.1007/s10555-011-9339-3 ↗
15. 10.1016/j.canlet.2017.05.01010.1016/j.canlet.2017.05.010 ↗
16. 10.1021/nl073290r10.1021/nl073290r ↗
17. 10.1172/JCI3884210.1172/JCI38842 ↗
18. 10.1016/j.ijpharm.2005.06.00910.1016/j.ijpharm.2005.06.009 ↗
19. Holle L, Song W, Holle E, et al. In vitro- and in vivo-targeted tumor lysis by an MMP2 cleavable melittin-LAP fusion protein. Int J Oncol. 2009;35:829–835.
20. 10.1016/j.actbio.2014.12.01810.1016/j.actbio.2014.12.018 ↗
21. 10.1016/S0076-6879(05)91004-510.1016/S0076-6879(05)91004-5 ↗
22. 10.4172/2157-7439.100036110.4172/2157-7439.1000361 ↗
23. 10.1016/j.jmmm.2010.09.00910.1016/j.jmmm.2010.09.009 ↗
24. 10.1016/j.ijpharm.2008.07.00610.1016/j.ijpharm.2008.07.006 ↗
25. 10.1016/j.colsurfb.2015.11.00910.1016/j.colsurfb.2015.11.009 ↗
26. 10.2174/221173850566617010915524710.2174/2211738505666170109155247 ↗
27. 10.1016/j.ejpb.2007.03.02310.1016/j.ejpb.2007.03.023 ↗
28. 10.1517/1742524080266279510.1517/17425240802662795 ↗
29. 10.2147/NSA.S3550610.2147/NSA.S35506 ↗
30. 10.1016/j.jmmm.2010.11.05910.1016/j.jmmm.2010.11.059 ↗
31. 10.1016/j.apsusc.2013.02.07210.1016/j.apsusc.2013.02.072 ↗
32. 10.1016/j.colsurfb.2014.03.00110.1016/j.colsurfb.2014.03.001 ↗
33. 10.1088/1468-6996/16/2/02350110.1088/1468-6996/16/2/023501 ↗
34. 10.1186/1556-276X-7-14410.1186/1556-276X-7-144 ↗
35. 10.1002/anie.20090156610.1002/anie.200901566 ↗
36. 10.1021/jp801632p10.1021/jp801632p ↗
37. 10.1007/s13738-017-1201-210.1007/s13738-017-1201-2 ↗
38. 10.1016/0022-1759(83)90303-410.1016/0022-1759(83)90303-4 ↗
39. 10.1016/j.actbio.2017.04.02910.1016/j.actbio.2017.04.029 ↗
40. 10.1016/0065-2571(84)90007-410.1016/0065-2571(84)90007-4 ↗
41. Dash S, Murthy PN, Nath L, et al. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67:217–223.
42. 10.1016/j.biomaterials.2017.04.02210.1016/j.biomaterials.2017.04.022 ↗
43. 10.3109/02652048.2015.101045910.3109/02652048.2015.1010459 ↗
44. 10.1006/jsre.2000.603010.1006/jsre.2000.6030 ↗
45. 10.1016/j.jmmm.2010.11.05910.1016/j.jmmm.2010.11.059 ↗